Menu
Innovation Observatory > Reports > Drugs > Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line

< Back

Ribociclib and Fulvestrant and PI3K Inhibitor (Buparlisib or Alpelisib) for HR Positive, HER2 Negative Postmenopausal Breast Cancer – Second or Third Line

Drugs

Cancer and Palliative Care

December 2017


The combination of ribociclib, fulvestrant, and buparlisib or alpelisib is being developed for the treatment of HR+ and HER2- locally recurrent or advanced metastatic breast cancer. Ribociclib is given by mouth (capsules). It acts by helping to slow the progression of cancer by inhibiting two certain types of proteins that play a role in ensuring that cancer cells do not grow uncontrollably. Buparlisib and alpelisib are other types of drugs that act by reducing tumour cell growth and survival. Both are also given by mouth. Fulvestrant is a drug that is given by injection and is already in use for the treatment of advanced breast cancer. If licensed, the combination of ribociclib, fulvestrant, and buparlisib or alpelisib will offer an additional treatment option for postmenopausal women with HR+, HER2-negative locally recurrent or advanced metastatic breast cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory

Twitter

 

Related Information

Ribociclib+Fulvestrant+PI3K Inhibitor for Breast cancer



Load More Related Posts
Get Alerts